| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Quest Diagnostics Inc.$198.49
-2.55 (-1.27%)
C 48Pipeline Score Diagnostics · Commercial
Market Cap
21.04 B
EPS
8.86
P/E Ratio
21.86 $
Value Trade
125.70 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.90 B
Operating CF
278.00 M
Total Assets
16.67 B
Total Liabilities
16.67 B
Equity
7.37 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
393.00 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 22, 2026
Overview
Volume
73.07 K
52 Week Range
160.02 - 213.50
% held by Insiders
0.49 %
% held by Institutions
95.49 %
Enterprise Value
27.12 B
Total Shares
109.89 M
Short %
3.13 %
Float Shares
109.45 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C48
Pipeline Score $2.1B
Pipeline ValueValuation Signal
4
Drugs Scored0.3x
rNPV / MCap Top 74%
Mid Cap (rank 236 of 905)
Percentile RankQuest Diagnostics Inc. carries a moderate pipeline score (48/100), with $2.4B risk-adjusted pipeline value, led by HDT 321 in Vaccine (Phase 1), across $64B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDT 321 Monoclonal antibody | Vaccine | Phase 1 | NCT06799013 | 26% | $1.9B | RECRUITING | 48 | STALLED | C (44) | Jul 1, 2027 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Quest Diagnostics Inc. (DGX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
DGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
DGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-DGX
Jun 17, 2026Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics has announced that it will release its second quarter financial results for 2026 on July 23, 2026, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. Eastern Time on the same day. Participants can access the call via specific phone numbers and will have the option to listen to a replay afterward.
Read more →-DGX
Jun 16, 2026Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics has released its 2025 Corporate Responsibility Report, highlighting its achievements in healthcare access, employee engagement, governance, and environmental sustainability. The report showcases significant contributions, including over one million discounted testing requisitions and improved employee retention. Additionally, the company has enhanced its governance structures and achieved ISO certification for environmental management.
Read more →-DGX
May 19, 2026Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics has announced a quarterly cash dividend of $0.86 per share, which will be paid on July 22, 2026, to shareholders of record on July 8, 2026. This decision reflects the company's ongoing commitment to returning value to its shareholders. Quest Diagnostics continues to play a crucial role in healthcare by providing diagnostic insights.
Read more →-DGX
Apr 28, 2026Quest Diagnostics Prices $500 Million of Senior Notes
Quest Diagnostics has announced the pricing of $500 million in senior notes due 2036. The company plans to use the proceeds for general corporate purposes, including repaying existing debt. The offering is expected to close on May 6, 2026, pending customary conditions. The announcement highlights Quest's ongoing commitment to healthcare diagnostics.
Read more →-DGX
Apr 17, 2026City of Hope to Evaluate Quest Diagnostics’ Haystack MRD® for Guiding Patient Management in Multiple Cancers
Quest Diagnostics has partnered with City of Hope to evaluate the Haystack MRD ctDNA test in managing patients with solid tumors, including breast, colorectal, ovarian, and prostate cancers. The multi-year study will involve around 500 patients and aims to improve early detection and treatment monitoring. The collaboration seeks to leverage advanced liquid biopsy technologies to enhance cancer care.
Read more →-DGX
Apr 16, 2026City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
Quest Diagnostics announced that City of Hope will evaluate its Haystack MRD test in clinical trials for patients with breast, colorectal, ovarian, and prostate cancers. The multi-year program aims to improve patient management by detecting minimal residual disease and monitoring treatment responses. The collaboration is expected to provide significant insights into the effectiveness of ctDNA testing in oncology.
Read more →-DGX
Feb 26, 2026Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
Quest Diagnostics announced that CFO Sam Samad will present at the Leerink 2026 Global Healthcare Conference. The presentation will cover the company's strategy, performance, and market trends. The event is scheduled for March 11, 2026, and will be available via live webcast and archived for later viewing.
Read more →-DGX
Feb 26, 2026Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer. With over 20 years of experience in business strategy and transformation, Beauvalot will lead the company's growth strategy and M&A efforts. He succeeds Dermot Shorten, who is retiring after overseeing numerous business combinations during his tenure.
Read more →-DGX
Feb 10, 2026Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Guidance for Full Year 2026; Increases Quarterly Dividend 7.5% to $0.86 Per Share
Quest Diagnostics reported strong financial results for Q4 and full year 2025, showcasing double-digit growth in revenues and earnings per share. The company also provided optimistic guidance for 2026 and announced a 7.5% increase in its quarterly dividend. CEO Jim Davis emphasized the company's commitment to clinical innovations and strategic collaborations.
Read more →-DGX
Feb 10, 2026Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter, Marking 15 Consecutive Years of Dividend Increases; Announces $1 Billion Increase in Share Repurchase Authorization
Quest Diagnostics has announced a 7.5% increase in its quarterly cash dividend, raising it to $0.86 per share, effective April 20, 2026. This marks the 15th consecutive year of dividend increases. Additionally, the company has authorized a $1 billion increase in its share repurchase program, supplementing the existing $0.4 billion available as of December 31, 2025.
Read more →-DGX
Feb 3, 2026Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
Quest Diagnostics has launched a novel blood test, the Quest Flow Cytometry MRD for Myeloma, which utilizes advanced flow cytometry methods to detect measurable residual disease in myeloma patients. This test offers sensitivity comparable to next-generation sequencing at a lower cost and features five-day specimen stability. It aims to improve patient care and monitoring in clinical trials.
Read more →-DGX
Jan 9, 2026Quest Diagnostics to Release Fourth Quarter and Full Year 2025 Financial Results on February 10, 2026
Quest Diagnostics has announced the release date for its fourth quarter and full year 2025 financial results, set for February 10, 2026. The results will be discussed in a conference call at 8:30 a.m. ET on the same day. Participants can access the call via phone or online, with replays available afterward.
Read more →-DGX
Dec 22, 2025Quest Diagnostics to Speak at the 44th Annual J.P. Morgan Healthcare Conference
Quest Diagnostics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Jim Davis and CFO Sam Samad will discuss the company's strategy and market developments. The session will be webcast live and available for later viewing.
Read more →Competitive Position
How DGX ranks across every disease it competes inCompetitive Position is a premium feature
See how DGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial